Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate the efficacy of sorafenib, compared to the best
supportive care (BSC), in two cohorts of patients who presented with advanced hepatocellular
carcinoma (HCC) based on etiology of hepatitis C virus.